Halozyme Therapeutics, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; comparisons are with Q1 2014 unless otherwise noted. Halozyme develops its rHuPH20 enzyme technology for drug delivery and oncology, including Enhanze collaborations and its lead candidate PEGPH20. The company reported continuing net losses.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 / prior date | Change / context |
|---|---|---|---|
| Total revenue | $18.7 million | $12.0 million | Up 56%, led by collaboration-product royalties. |
| Product sales, net | $9.9 million | $8.6 million | Hylenex sales rose to $3.8 million from $2.5 million; bulk rHuPH20 sales to Roche were $6.1 million. |
| Royalties | $6.8 million | $0.8 million | Increase primarily reflected Roche’s Herceptin SC sales. |
| Collaborative-agreement revenue | $2.0 million | $2.6 million | Lower reimbursements for research and development services. |
| Cost of product sales | $6.5 million | $5.5 million | Gross profit was approximately $12.2 million, or 65% of revenue, versus $6.4 million, or 54%. |
| Research and development | $16.7 million | $21.4 million | Overall decline masked PEGPH20 spending growth to $12.9 million from $6.7 million. |
| Selling, general and administrative | $9.4 million | $10.3 million | Down 8%, primarily lower compensation expense. |
| Operating loss | $13.9 million | $25.2 million | Improved with higher revenue and lower operating expenses. |
| Net loss / loss per share | $15.1 million / $0.12 | $26.5 million / $0.22 | Loss narrowed; weighted-average shares increased to 125.3 million from 118.9 million. |
| Operating cash flow | $(13.8) million | $(17.6) million | Cash use declined by $3.8 million. |
| Cash and marketable securities | $128.5 million at March 31 | $135.6 million at December 31, 2014 | Cash and equivalents were $44.3 million; marketable securities were $84.2 million. |
| Debt | Approximately $49.7 million | Approximately $49.9 million net at year-end | 7.55% interest; interest-only payments through January 2016; maturity January 2018. |
| Stockholders’ equity | $37.5 million | $41.4 million at December 31, 2014 | Accumulated deficit was $465.5 million. |
Material changes and business developments
- Revenue growth was driven primarily by royalties, while product sales also increased. Royalty revenue is reported one quarter after collaborators’ sales.
- R&D expense declined overall as spending on ultrafast insulin, Hylenex and Enhanze programs fell; PEGPH20 spending nearly doubled amid increased clinical activity.
- In March 2015, Halozyme met with the FDA regarding PEGPH20. The company plans a Phase 3 pancreatic cancer study, but initiation requires an approved companion-diagnostic strategy.
- The company continued its workforce and program focus following a November 2014 reorganization that reduced headcount by approximately 13%, primarily in R&D. The remaining restructuring liability was paid in Q1.
- Disclosure controls and procedures were assessed as effective; the filing reports no material change in internal control over financial reporting and no material adverse legal proceeding.
Outlook, risks and contingencies
- Management expects 2015 net cash burn of approximately $35–$45 million and says available cash, cash equivalents and marketable securities are expected to fund operations for at least the next 12 months. The company cautions that resources may not last until it becomes cash-flow positive, if ever.
- Management expects R&D expense to rise as PEGPH20 development advances and SG&A to increase. Revenue under collaborations may fluctuate with collaborator activity, milestones, product sales and requests for services or bulk enzyme.
- PEGPH20’s clinical development carries a significant safety risk: thromboembolic events prompted a 2014 clinical hold and protocol revisions. The company and data monitoring committee continue to monitor event rates; the trial could be halted again.
- Q1 2015 interim Phase 2 results included longer PFS among patients with high baseline tumor hyaluronan, but these are interim subgroup findings. FDA feedback makes an approved companion diagnostic a prerequisite for the planned Phase 3 study.
- Debt is secured by substantially all company assets other than specified excluded assets, and includes restrictive covenants and default provisions that could permit acceleration. Halozyme reported covenant compliance at March 31, 2015.
- Additional financing may be needed; availability and terms are uncertain. Equity financing could dilute shareholders, while debt financing could add payment obligations and restrictions.
- Other material risks include clinical or regulatory setbacks, reliance on collaborators and contract manufacturers, potential rHuPH20 antibody concerns, product adoption and reimbursement, and the company’s history of losses and negative operating cash flow.
Important facts for investors to verify
- Whether PEGPH20’s safety profile and efficacy support Phase 3 progression, and whether the required companion diagnostic is approved and ready in time.
- Whether Roche and other collaborators sustain product sales and royalty growth, and how royalty reporting lags affect quarterly results.
- Whether 2015 cash burn stays within the $35–$45 million outlook and liquidity remains adequate relative to development plans and debt obligations.
- Whether manufacturing capacity, supply quality and regulatory qualifications can support clinical trials and potential commercialization.
- Whether the reported interim high-hyaluronan subgroup findings are confirmed in adequately powered studies and translate into clinically meaningful benefit.